From ICANS to MNT: The CXCL12/CXCR4-MMP Axis as the Molecular Basis of Basal Ganglia-Selective Neurotoxicity after BCMA CAR T-Cell Therapy
CAR T-cell therapies have fundamentally improved the treatment of multiple myeloma. However, weeks to months after treatment with CAR T cells directed against the surface marker BCMA, some patients develop a rare, often permanent and sometimes fatal movement disorder resembling Parkinson's disease. Why this damage specifically affects the basal ganglia – brain regions that are central to the control of movement – is still unknown.
PD Dr. Nora Möhn and her team are investigating whether the messenger molecule CXCL12 and its receptor CXCR4, which is particularly abundant on nerve cells of the basal ganglia, play a key role in this process. To this end, the researchers analyse blood and cerebrospinal fluid samples from treated patients and test the effects in cell models. The aim is to identify patients at increased risk at an early stage and to develop targeted therapies that do not impair the anti-tumour effect of CAR T cells.